Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Late-Life Treatment-Resistant Depression
NCT02263248Phase 2Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine in major depressive disorder (MDD), sponsored by Center for Addiction and Mental Health. Started Dec 2014; status: completed.
02
Drugs
buprenorphine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02263248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263248.